Cargando…

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Detalles Bibliográficos
Autores principales:	Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632659/ https://www.ncbi.nlm.nih.gov/pubmed/34021252 http://dx.doi.org/10.1038/s41375-021-01297-z

Ejemplares similares

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023)

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
por: Vaxman, I., et al.
Publicado: (2022)

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP
por: Abdallah, N., et al.
Publicado: (2022)

N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
por: Milani, Paolo, et al.
Publicado: (2016)

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
por: Merlini, G, et al.
Publicado: (2016)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010)

Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome
por: Muchtar, Eli, et al.
Publicado: (2022)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
por: Al Saleh, Abdullah S., et al.
Publicado: (2022)

Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
por: Visram, Alissa, et al.
Publicado: (2020)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

NT-proBNP in Children With Left to Right Shunt and Dilated Cardiomyopathy
por: Koura, Hala Mahmoud, et al.
Publicado: (2016)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
por: Lewis, Robert A., et al.
Publicado: (2020)

Use of NT-proBNP in weaning from mechanical ventilation
por: Martini, A, et al.
Publicado: (2011)

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure
por: Linssen, G. C. M., et al.
Publicado: (2018)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2020)

P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change
por: D’Souza, Anita, et al.
Publicado: (2021)

NT‐proBNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure
por: Whitman, Isaac R., et al.
Publicado: (2019)

The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
por: Sedlak, Tara L, et al.
Publicado: (2008)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM)
por: Hoevelmann, J., et al.
Publicado: (2021)

BNP and NT-proBNP in patients with acute myocardial infarction complicated by cardiogenic shock: results from the IABP Shock trial
por: Lemm, H, et al.
Publicado: (2010)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death
por: Warsame, R, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m3s35gnernhgdrdbmuq8a4u040